Recently presented studies support the utility of Genestrat and Veristrat for detecting actionable mutations and guiding therapy in drug-resistant lung cancer patients.
GenomeWeb spoke to Aebersold this week from New York to get his thoughts on the meeting and what is happening in the world of proteomics more generally.
CareFirst covers more than 3 million patients in Maryland, Washington DC, and Virginia, and is one several payors to recently issue a coverage decision for Vermillion.
The project combined proteomic, lipidomic, and metabolomic analyses of 174 knockout yeast strains using a high-throughput mass spectrometry workflow.
The company believes its phosphotyrosine enrichment reagents will enable deeper phosphoproteomic studies and aid in drug and diagnostics development.
In Science this week: global genetic diversity map, and more.
The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.
In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."
Stat News reports that there's muted opposition to the Kuwaiti DNA database law.